In breast cancer, molecular alterations involving the CyclinD-CDK4/6-Rb pathway frequently occur [3] and strategies to target this pathway have recently been proven to be effective in patients with advanced breast cancer, particularly those with hormone receptor positive (HR+), HER2 negative (HER2neg) tumors [4]. This evidence concerns the gene ERBB2 and breast carcinoma.